• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge.

作者信息

Zhang Yi-Chen, Zhou Qing, Chen Zhi-Hong, Zhang Ming-Feng, Yang Jin-Ji, Tu Hai-Yan, Zhang Xu-Chao, Xu Chong-Rui, Yan Hong-Hong, Peng Xiao-Xiao, Bai Xiao-Yan, Chuai Shao-Kun, Ye Jun-Yi, Wu Yi-Long

机构信息

The Second School of Clinical Medicine, Southern Medical University, Guangzhou 510280, China; Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital and Guangdong Academy of Medical Sciences, Guangzhou 510080, China.

出版信息

Sci Bull (Beijing). 2019 Apr 30;64(8):499-503. doi: 10.1016/j.scib.2019.03.031. Epub 2019 Mar 28.

DOI:10.1016/j.scib.2019.03.031
PMID:36659737
Abstract
摘要

相似文献

1
The spatiotemporal evolution of EGFR C797S mutation in EGFR-mutant non-small cell lung cancer: opportunities for third-generation EGFR inhibitors re-challenge.表皮生长因子受体（EGFR）突变的非小细胞肺癌中EGFR C797S突变的时空演变：第三代EGFR抑制剂重新挑战的机遇
Sci Bull (Beijing). 2019 Apr 30;64(8):499-503. doi: 10.1016/j.scib.2019.03.031. Epub 2019 Mar 28.
2
In-silico evidences for binding of Glucokinase activators to EGFR C797S to overcome EGFR resistance obstacle with mutant-selective allosteric inhibition.基于计算机的证据表明，葡萄糖激酶激活剂与 EGFR C797S 结合，通过突变体选择性别构抑制克服 EGFR 耐药障碍。
Comput Biol Chem. 2018 Jun;74:167-189. doi: 10.1016/j.compbiolchem.2018.03.026. Epub 2018 Mar 29.
3
The Allelic Context of the C797S Mutation Acquired upon Treatment with Third-Generation EGFR Inhibitors Impacts Sensitivity to Subsequent Treatment Strategies.第三代EGFR抑制剂治疗后获得的C797S突变的等位基因背景影响对后续治疗策略的敏感性。
Clin Cancer Res. 2015 Sep 1;21(17):3924-33. doi: 10.1158/1078-0432.CCR-15-0560. Epub 2015 May 11.
4
Recent updates on third generation EGFR inhibitors and emergence of fourth generation EGFR inhibitors to combat C797S resistance.第三代表皮生长因子受体（EGFR）抑制剂的最新进展以及第四代EGFR抑制剂的出现以对抗C797S耐药性。
Eur J Med Chem. 2017 Dec 15;142:32-47. doi: 10.1016/j.ejmech.2017.05.027. Epub 2017 May 11.
5
p38α MAP kinase inhibitors to overcome EGFR tertiary C797S point mutation associated with osimertinib in non-small cell lung cancer (NSCLC): emergence of fourth-generation EGFR inhibitor.p38α丝裂原活化蛋白激酶抑制剂克服非小细胞肺癌（NSCLC）中与奥希替尼相关的表皮生长因子受体（EGFR）三级C797S点突变：第四代EGFR抑制剂的出现
J Biomol Struct Dyn. 2022 Apr;40(7):3046-3059. doi: 10.1080/07391102.2020.1844801. Epub 2020 Nov 11.
6
EGFR-Mutated Lung Cancers Resistant to Osimertinib through EGFR C797S Respond to First-Generation Reversible EGFR Inhibitors but Eventually Acquire EGFR T790M/C797S in Preclinical Models and Clinical Samples.奥希替尼耐药的 EGFR 突变型肺癌对第一代可逆性 EGFR 抑制剂敏感，但在临床前模型和临床样本中最终会获得 EGFR T790M/C797S 耐药突变。
J Thorac Oncol. 2019 Nov;14(11):1995-2002. doi: 10.1016/j.jtho.2019.07.016. Epub 2019 Aug 1.
7
Efficacy of immunotherapy targeting the neoantigen derived from epidermal growth factor receptor T790M/C797S mutation in non-small cell lung cancer.针对表皮生长因子受体 T790M/C797S 突变的新型抗原的免疫疗法在非小细胞肺癌中的疗效。
Cancer Sci. 2020 Aug;111(8):2736-2746. doi: 10.1111/cas.14451. Epub 2020 Jun 18.
8
Two case reports of non-small cell lung cancer patients harboring acquired T790M--C797S benefit from immune checkpoint inhibitor combined with platinum-based doublet chemotherapy.两例携带获得性T790M-C797S的非小细胞肺癌患者受益于免疫检查点抑制剂联合铂类双药化疗的病例报告。
Ann Transl Med. 2022 Jun;10(12):719. doi: 10.21037/atm-22-2436.
9
search of triple mutant T790M/C797S allosteric inhibitors to conquer acquired resistance problem in non-small cell lung cancer (NSCLC): a combined approach of structure-based virtual screening and molecular dynamics simulation.寻找三重突变 T790M/C797S 变构抑制剂以克服非小细胞肺癌（NSCLC）中的获得性耐药问题：基于结构的虚拟筛选和分子动力学模拟的联合方法。
J Biomol Struct Dyn. 2021 Mar;39(4):1491-1505. doi: 10.1080/07391102.2020.1734092. Epub 2020 Mar 6.
10
Overcoming C797S mutation: The challenges and prospects of the fourth-generation EGFR-TKIs.克服 C797S 突变：第四代 EGFR-TKIs 的挑战与展望。
Bioorg Chem. 2022 Nov;128:106057. doi: 10.1016/j.bioorg.2022.106057. Epub 2022 Aug 1.

引用本文的文献

1
Survival benefit of combinatorial osimertinib rechallenge and entrectinib in an EGFR-mutant NSCLC patient with acquired LMNA-NTRK1 fusion following osimertinib resistance.奥希替尼耐药后，联合使用奥希替尼再挑战和恩曲替尼对一名获得性LMNA-NTRK1融合的EGFR突变非小细胞肺癌患者的生存获益。
Respirol Case Rep. 2022 Oct 17;10(11):e01054. doi: 10.1002/rcr2.1054. eCollection 2022 Nov.
2
A Novel Third-generation EGFR Tyrosine Kinase Inhibitor Abivertinib for EGFR T790M-mutant Non-Small Cell Lung Cancer: a Multicenter Phase I/II Study.一种新型第三代 EGFR 酪氨酸激酶抑制剂阿维替尼治疗 EGFR T790M 突变型非小细胞肺癌：一项多中心 I/II 期研究。
Clin Cancer Res. 2022 Mar 15;28(6):1127-1135. doi: 10.1158/1078-0432.CCR-21-2595.
3
Targeting epidermal growth factor-overexpressing triple-negative breast cancer by natural killer cells expressing a specific chimeric antigen receptor.
利用表达特异性嵌合抗原受体的自然杀伤细胞靶向表皮生长因子过表达的三阴性乳腺癌。
Cell Prolif. 2020 Aug;53(8):e12858. doi: 10.1111/cpr.12858. Epub 2020 Jun 27.